NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx’s Preservative-Free Ketamine Application

NRx Pharmaceuticals (Nasdaq: NRXP) received a letter from the FDA Office of Generic Drugs indicating preliminary alignment on labeling for its preservative-free ketamine Abbreviated New Drug Application.

Rhea-AI Summary

NRx Pharmaceuticals (Nasdaq: NRXP) received a letter from the FDA Office of Generic Drugs indicating preliminary alignment on labeling for its preservative-free ketamine Abbreviated New Drug Application. Label comments were limited to minor formatting; the company expects to submit a final label this month and anticipates a GDUFA decision in Summer 2026.

The company previously received a preliminary determination of bioequivalence. NRx says the product is U.S.-manufactured and could help augment domestic ketamine supply during current backorders; the labeling remains subject to final supervisory review.

Positive

• Preliminary FDA labeling alignment for preservative-free ketamine
• Preliminary bioequivalence determination reported
• U.S. manufacturing could augment domestic ketamine supply amid backorders

Negative

• Labeling determination remains preliminary pending final supervisory review
• Final approval still pending GDUFA decision in Summer 2026
• Regulatory timing uncertainty could delay commercial availability

Argus Apr 6 session

+2.27% close to close Open Argus

Details

News Market Reaction – NRXP

On Apr 6, the day this news came out, NRXP closed 2.27% above the previous close.

Data tracked by StockTitan Argus for the Apr 6 session.

Key Figures

Shelf registration size: $150,000,000 Unsold prior securities: $78,644,060 Shares outstanding: 29,605,150 shares +5 more

Shelf registration size

$150,000,000

Amended S-3/A filed Dec 12, 2025

Unsold prior securities

$78,644,060

Carried forward under Rule 415(a)(6)

Shares outstanding

29,605,150 shares

As of Dec 11, 2025 in S-3/A

Cash balance

$7.8 million

Year-end 2025 from full-year results

Loss from operations

$16.2 million

Full-year 2025 results

Net loss

$28.9 million

Nine months ended Sep 30, 2025

Cash and equivalents

$7.2 million

As of Sep 30, 2025

Working capital deficit

$28.6 million

As of Sep 30, 2025

Historical Context

5 past events · Latest: Mar 30

5 events

1. Mar 30

   AI partnership

   24h Move

   -4.6%

   Announced AI-based depression monitoring partnership for psychiatry clinics.

2. Mar 24

   Full-year results

   24h Move

   +20.3%

   Reported 2025 results with cash update and favorable ketamine signals.

3. Mar 19

   Earnings date set

   24h Move

   -3.2%

   Scheduled FY2025 earnings call and corporate update date and time.

4. Mar 17

   Bioequivalence update

   24h Move

   -6.3%

   FDA indicated no bioequivalence deficiencies for ketamine ANDA.

5. Mar 16

   NDA path clarity

   24h Move

   +12.1%

   FDA Type C minutes confirmed NDA path for NRX‑100 in depression.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

generic drug user fee act, office of generic drugs, abbreviated new drug application, new drug application, +1 more

5 terms

generic drug user fee act regulatory

"decision on approval under the Generic Drug User Fee Act (GDUFA) in Summer 2026."

A federal program that lets generic drug makers pay annual and application fees to the U.S. drug regulator to fund and speed up the review and oversight of generic medicines. For investors, it matters because the fees and resulting review timelines influence how fast generic competitors reach the market, the cost structure for manufacturers, and the timing of revenue and margin changes—similar to paying for expedited processing that affects product launch schedules.

office of generic drugs regulatory

"letter from the FDA Office of Generic Drugs indicating preliminary alignment"

Office of Generic Drugs is the regulatory unit that reviews and approves generic versions of prescription medicines, ensuring they match brand-name drugs in safety, strength, quality and performance. Think of it as a quality-control office that decides when cheaper, interchangeable copies can enter the market; its decisions affect competition, drug pricing and revenue prospects for both brand and generic drugmakers, so investors watch its approvals and guidance closely.

abbreviated new drug application regulatory

"final supervisory review of NRx’s Abbreviated New Drug Application with anticipated approval"

An abbreviated new drug application is a regulatory submission used to gain approval to market a generic version of an already approved prescription medicine by showing it is equivalent in effect and safety to the original product, without repeating full clinical trials. For investors, an approval signals a lower-cost competitor entering the market that can quickly capture sales from the branded drug, similar to a generic knock‑off replacing a name‑brand item on store shelves.

new drug application regulatory

"preparing a New Drug Application under Fast Track Designation to expand the use"

A new drug application is a formal request submitted to government regulators seeking approval to market a new medicine. It is like a detailed proposal that shows the drug has been tested for safety and effectiveness. For investors, receiving approval signals that the drug may soon become available for sale, potentially leading to revenue growth and impacting the company's value.

fast track designation regulatory

"preparing a New Drug Application under Fast Track Designation to expand the use"

Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• NRx has received a letter from the FDA Office of Generic Drugs indicating preliminary alignment on labeling for NRx’s preservative-free ketamine product. Labeling remains subject to final supervisory review.
• NRx previously received a preliminary determination of bioequivalence for this product.
• The Company continues to anticipate a decision on approval under the Generic Drug User Fee Act (GDUFA) in Summer 2026.
  
  

WILMINGTON, Del., April 06, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced that it has received a letter from the Labeling Program of the FDA Office of Generic Drugs whose only comments were limited to minor formatting changes to the proposed label for the Company's preservative-free ketamine product. The Company expects to submit the final label this month. The determination is deemed preliminary until final supervisory review of NRx’s Abbreviated New Drug Application with anticipated approval in Summer 2026.

This determination by FDA is meaningful in that NRx’s product has the potential to substantially augment the supply of US manufactured ketamine at a time when multiple suppliers of ketamine are advising the medical community that they are on backorder. NRx’s preservative free product is manufactured in the United States at a time when the FDA has deemed ketamine to be a highly strategic product and recently awarded a Commissioner’s National Priority Voucher for a new US manufacturing source of ketamine drug ingredient. A key administration focus has been the “re-shoring” of critical elements of the US drug supply.

“We deeply appreciate the FDA’s timely review of the proposed labeling for our generic drug application and look forward to an ongoing collaborative relationship,” said Dr. Jonathan C. Javitt, MD, MPH, NRx’s CEO and Chairman.”

In addition to the pending ANDA application for Preservative Free Ketamine, NRx (as announced yesterday) is preparing a New Drug Application under Fast Track Designation to expand the use of intravenous ketamine to treat patients with severe depression, who may have suicidal ideation.

About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA), and initiated a New Drug Application filing for NRX-100 with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal ideation in patients with depression, including bipolar depression.

Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The Company has reported regulatory milestones as they have been achieved but has not predicted the outcome of any future regulatory determination. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.

For further information:
Brian Korb
Managing Partner, astr partners
(917) 653-5122
brian.korb@astrpartners.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did NRx (NRXP) announce about FDA labeling for preservative-free ketamine on April 6, 2026?

The company reported a preliminary FDA labeling alignment, with only minor formatting comments. According to the company, the final label will be submitted this month and remains subject to supervisory review.

Has NRx (NRXP) established bioequivalence for its preservative-free ketamine?

NRx reported a preliminary determination of bioequivalence for the product. According to the company, that determination preceded the labeling letter and supports the pending ANDA review.

When does NRx (NRXP) expect a regulatory decision on its preservative-free ketamine application?

The company continues to anticipate a GDUFA decision in Summer 2026. According to the company, final approval timing depends on supervisory review and standard FDA processes.

Will NRx's preservative-free ketamine be manufactured in the United States?

Yes; NRx says the preservative-free product is manufactured in the United States. According to the company, U.S. production may help augment domestic ketamine supply during current backorders.

Does the FDA labeling letter guarantee approval for NRx (NRXP)'s ketamine product?

No; the letter reflects preliminary alignment but does not guarantee approval. According to the company, labeling remains subject to final supervisory review before any approval is granted.